Daewon Pharmaceutical Risk (Part 1): Operating profit and net profit decline for 3rd consecutive year, ‘growth red light’… ‘Capital erosion’ of subsidiaries, ‘swaying’ by short-term borrowings and debt ratio

• 페북
• 트윗
• 카톡
• 기타